Allergan, Inc.
NYSE: AGN
AGN Articles
Building on a turn toward more equity investments in the second quarter of this year, the top 50 hedge funds boosted their equity positions by nearly 3% in the third quarter.
Published:
Last Updated:
With the Republicans now set to control both Congress and the White House, many on Wall Street feel that there could be far less scrutiny on drug pricing.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Monday morning include AbbVie, Chevron, Home Depot, Nike, Qualcomm and VMware.
Published:
Last Updated:
Alkermes' positive Phase 3 results for its novel antidepressant is serving as a rising tide — a storm surge even — for many biotech companies in the depression space.
Published:
Last Updated:
Tobira Therapeutics shares skyrocketed on Tuesday after Allergan announced that it will acquire the company.
Published:
Last Updated:
The goal of Allergan’s bid for Vitae Pharmaceuticals is to bolster its dermatology product pipeline, and Vitae shareholders appear happy to oblige.
Published:
Last Updated:
In one of the longest running bidding wars in recent times, Pfizer has finally reeled in cancer-drug maker Medivation.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Friday morning include AK Steel, Allergan, ArcelorMittal, Symantec, Teck Resources, US Steel, Emerson and Hormel.
Published:
Last Updated:
Credit Suisse has run bullish and bearish scenarios for what the firm feels is a reasonable upside and downside for each of its large cap pharmaceutical stocks.
Published:
Last Updated:
Allergan reported mixed second-quarter 2016 results and announced share buybacks before markets opened Monday morning.
Published:
Last Updated:
Teva Pharmaceutical Industries is scheduled to release its second-quarter financial results before the markets open on Thursday.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Monday morning include Allergan, General Electric, Hewlett Packard Enterprise, Southwest Airlines and Williams Companies.
Published:
Last Updated:
Lucky for Teva Pharmaceuticals, interest rates on all kinds of debt have never been lower in recorded human history, and they keep getting lower even beyond basic logic.
Published:
Last Updated:
Even though the trend toward generic drugs is only likely to grow, the drug price pressures hanging over the sector also hurt most generic drug makers.
Published:
Last Updated:
Ever since the infamous Hillary Clinton tweet about pharmaceutical drug pricing, the biotech and specialty pharmaceutical stocks have taken a huge beating. In some cases, the markets have knocked...
Published:
Last Updated: